Receptor-mediated brain delivery in MPS II: a platform turning point for rare disease therapeutics

References

[1] Muenzer J,Harmatz P.An intravenous brain-penetrant enzyme therapy for mucopolysaccharidosis II.N Engl J Med2026;394:39-50

[2] Denali Therapeutics. Press Release. Denali therapeutics announces U.S. FDA approval of AVLAYAH^TM (tividenofusp alfa-eknm) for treatment of hunter syndrome (MPS II). 2026. Available from: https://investors.denalitherapeutics.com/node/11606/pdf [Last accessed on 23 Sep 2026]

[3] U.S. Food and Drug Administration. FDA news release. FDA approves drug to treat neurologic manifestations of hunter syndrome. 2026. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome [Last accessed on 23 Sep 2026]

[4] Kariolis MS,Getz JA.Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys.Sci Transl Med2020;12:eaay1359

[5] Arguello A,Calvert ME.Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.J Exp Med2022;219:e20211057 PMCID:PMC8932535

[6] Fukatsu T,Furihata T.Transferrin receptor-targeting property of pabinafusp alfa facilitates its uptake by various types of human brain-derived cells in vitro.Front. Drug Deliv2023;3:1082672 PMCID:PMC12363330

[7] Okuyama T,Sakai N.Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial.Mol Ther2019;27:456-64 PMCID:PMC6391590

[8] Okuyama T,Sakai N.A phase 2/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II.Mol Ther2021;29:671-9 PMCID:PMC7854283

[9] Bonvicini G,Sandersjöö L,Syvänen S.The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo.Fluids Barriers CNS2025;22:36 PMCID:PMC11980351

[10] Bien-Ly N,Bumbaca D.Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.J Exp Med2014;211:233-44 PMCID:PMC3920563

[11] Niewoehner J,Collin L.Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.Neuron2014;81:49-60

[12] Muenzer J,Harmatz P.Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: results from a phase 2/3 randomized study.Mol Genet Metab2022;137:127-39 PMCID:PMC10826424

[13] Argueta C,Wang S.A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2/3 clinical trial and extension study of intrathecal idursulfase.Mol Genet Metab2025;144:109055

[14] Saikia S,Khan S.The complementary strength of the AAV9 gene therapy in hematopoietic stem cells transplanted into MPS IVA mice.Mol Genet Metab2026;147:109607

[15] Harmatz P,Martins AM.α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: a phase 1/2 trial.Mol Ther2024;32:609-18 PMCID:PMC10928130

[16] Kida S,Yoden E.Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice.Mol Ther Methods Clin Dev2023;29:439-49 PMCID:PMC10220318

[17] Yamamoto R,Tanaka N.Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II.Mol Genet Metab Rep2021;27:100758 PMCID:PMC8081988

[18] Arguello A,Thomsen ER.Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.JCI Insight2021;6:e145445 PMCID:PMC8525587

[19] Ullman JC,Getz JA.Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice.Sci Transl Med2020;12:eaay1163

[20] George K,Zhou S.Novel transferrin receptor-mediated enzyme replacement therapy efficiently treats myogenic and neurogenic aspects of Pompe disease in mice.Mol Ther Methods Clin Dev2025;33:101547 PMCID:PMC12395447

[21] Boado RJ,Hui EK.Reduction in brain heparan sulfate with systemic administration of an IgG trojan horse-sulfamidase fusion protein in the mucopolysaccharidosis type IIIA mouse.Mol Pharm2017;15:602-8

[22] Muenzer J,Harmatz P.Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.Mol Genet Metab2022;137:92-103 PMCID:PMC10826456